Literature DB >> 21079220

Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report.

Serena Guiducci1, Francesco Porta, Riccardo Saccardi, Stefano Guidi, Lidia Ibba-Manneschi, Mirko Manetti, Benedetta Mazzanti, Simone Dal Pozzo, Anna Franca Milia, Silvia Bellando-Randone, Irene Miniati, Ginevra Fiori, Rossana Fontana, Laura Amanzi, Francesca Braschi, Alberto Bosi, Marco Matucci-Cerinic.   

Abstract

BACKGROUND: Mesenchymal stem cells can differentiate into endothelial cells and participate in angiogenesis in adults. In experimental models of acute myocardial infarction, mesenchymal stem cells led to the recovery of cardiac function through the formation of a new vascular network.
OBJECTIVE: To describe treatment with intravenous infusions of expanded autologous mesenchymal stem cells in 1 patient with critical limb ischemia due to systemic sclerosis.
DESIGN: Case report.
SETTING: The rheumatology unit at the University of Florence, Florence, Italy. PATIENT: A woman, aged 34 years, with systemic sclerosis who developed acute gangrene of the upper and lower limbs. INTERVENTION: 3 intravenous pulses of expanded autologous mesenchymal stem cells. MEASUREMENTS: Angiography, skin histopathology, and immunohistochemistry.
RESULTS: Areas of necrotic skin were reduced after the first mesenchymal stem-cell infusion. After the third infusion, angiography showed revascularization of the patient's extremities. Skin section analysis revealed cell clusters with tubelike structures, and angiogenic factors were strongly expressed. LIMITATION: Causality cannot be established by a single case.
CONCLUSION: In patients with systemic sclerosis who have severe peripheral ischemia, intravenous infusion of expanded autologous mesenchymal stem cells may foster the recovery of the vascular network, restore blood flow, and reduce skin necrosis. PRIMARY FUNDING SOURCE: Fondazione Cassa di Risparmio di Pistoia e Pescia (partial funding).

Entities:  

Mesh:

Year:  2010        PMID: 21079220     DOI: 10.7326/0003-4819-153-10-201011160-00007

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  35 in total

Review 1.  Mesenchymal stem cells: potential for therapy and treatment of chronic non-healing skin wounds.

Authors:  Giovanni Marfia; Stefania Elena Navone; Clara Di Vito; Nicola Ughi; Silvia Tabano; Monica Miozzo; Carlo Tremolada; Gianni Bolla; Chiara Crotti; Francesca Ingegnoli; Paolo Rampini; Laura Riboni; Roberta Gualtierotti; Rolando Campanella
Journal:  Organogenesis       Date:  2015       Impact factor: 2.500

Review 2.  The potential role of adult stem cells in the management of the rheumatic diseases.

Authors:  Tiziana Franceschetti; Cosimo De Bari
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-04-20       Impact factor: 5.346

3.  [Critical limb ischemia in systemic sclerosis].

Authors:  M O Becker; G Riemekasten
Journal:  Z Rheumatol       Date:  2012-06       Impact factor: 1.372

4.  Isolation and characterization of putative mesenchymal stem cells from mammalian gut.

Authors:  Yulong Tao; Sang Zhu; Hong Yang; Fei Huang; Hui Fu; Xia Tao
Journal:  Cytotechnology       Date:  2016-10-18       Impact factor: 2.058

Review 5.  [Mesenchymal stem/stroma cells : Therapeutic potential in the treatment of autoimmune diseases].

Authors:  R Schäfer; T Daikeler
Journal:  Z Rheumatol       Date:  2016-10       Impact factor: 1.372

Review 6.  Vascular stem cells-potential for clinical application.

Authors:  Sadie C Slater; Michele Carrabba; Paolo Madeddu
Journal:  Br Med Bull       Date:  2016-06       Impact factor: 4.291

7.  MALP-2, an agonist of TLR6, promotes the immune status without affecting the differentiation capacity of umbilical cord mesenchymal stem cells.

Authors:  Xiuli Wu; Lian Xu; Yangmei Shen; Na Yu; Yan Zhang; Tao Guo
Journal:  Exp Ther Med       Date:  2017-10-03       Impact factor: 2.447

Review 8.  Mesenchymal stem cell treatments in rheumatology: a glass half full?

Authors:  Alan Tyndall
Journal:  Nat Rev Rheumatol       Date:  2013-11-12       Impact factor: 20.543

Review 9.  Mesenchymal stem cells as a treatment for peripheral arterial disease: current status and potential impact of type II diabetes on their therapeutic efficacy.

Authors:  Jinglian Yan; Guodong Tie; Ting Yu Xu; Katharine Cecchini; Louis M Messina
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 10.  Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis.

Authors:  Alexandre T J Maria; Marie Maumus; Alain Le Quellec; Christian Jorgensen; Danièle Noël; Philippe Guilpain
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.